Knee

EQS-News: Grünenthal reports strong 2023 results with record revenue and continued investments in R&D and acquisitions

Retrieved on: 
Wednesday, April 10, 2024
Trigeminal neuralgia, Knee, Growth, Rheumatoid arthritis, Neuropathic pain, Pain, GRM, DPN, ESG, Patient, Prednisolone, Research, Sustainalytics, Breakthrough, Glucocorticoid, Quality of life, PSNP, Research and development, Investment, Diabetic neuropathy, NOP, Kyowa Kirin, Osteoarthritis, RTX, Food, FDA, Corporation, Pharmaceutical industry

In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.

Key Points: 
  • In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.
  • Grünenthal owns 51 percent of the new enterprise Grünenthal Meds and intends to acquire the remaining share in 2026.
  • Aachen, Germany, 25 March 2024 – Grünenthal, the leading pharmaceutical company in pain research and management, released its 2023 full-year results, announcing a double-digit revenue growth.
  • The 2023 results were driven by strong business performance in the United States, Latin America and Europe.

Global Sports Medicine Devices Market Set for Significant Growth, Poised to Reach $11 Billion by 2028 Driven by Technological Advances and Injury Prevention Trends - Long-term Forecast to 2033 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 9, 2024
Medical Devices, Health, Sports, Other Sports, Fitness & Nutrition, General Sports, Injury, Knee, Therapy, Sports medicine, Marketing, Hospital, Foot, Growth, Acquisition, Rehabilitation, Medical device

The global market for sports medicine devices has observed a robust expansion in recent years, with projections indicating a continued trajectory of growth.

Key Points: 
  • The global market for sports medicine devices has observed a robust expansion in recent years, with projections indicating a continued trajectory of growth.
  • The sector is forecasted to burgeon from $7.44 billion in 2023 to an estimable $8.06 billion in 2024.
  • As we look toward the future, the market is set to reach new heights, expected to achieve $11 billion by 2028, growing at a steady CAGR of 8.1%.
  • Innovation remains at the forefront of the sports medicine device market with leading companies at the helm of technological breakthroughs.

Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine Technology Partner

Retrieved on: 
Monday, March 25, 2024
Knee, Health, Regeneration, Sport, Shoulder, Hip, UFC Performance Institute, Partnership, Patient, Life, Research, Athlete, Surgeon, Octagon, SNN, Safety, Sports medicine, UFC, Smith & Nephew, Rehabilitation

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been named the Preferred Sports Medicine Technology Partner of UFC – the world’s premier mixed martial arts organization and one of the foremost global brands in all of sports.

Key Points: 
  • Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has been named the Preferred Sports Medicine Technology Partner of UFC – the world’s premier mixed martial arts organization and one of the foremost global brands in all of sports.
  • “We’re thrilled to have Smith+Nephew join us for the first time as an Official UFC Partner,” said Robby Miller, Vice President, UFC Global Partnerships.
  • “Through hard work, significant investment, and groundbreaking innovations like the UFC Performance Institute, UFC has become the industry leader in athlete health and safety in combat sports.
  • We are proud to partner with UFC and share a common goal to get patients back in the game quickly, safely, and effectively,” said Scott Schaffner, President Sports Medicine, Smith+Nephew.

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Retrieved on: 
Wednesday, March 13, 2024
Knee, Congress, Biologics license application, Patient, ATMP, Research, World Congress, OARSI, European Medicines Agency, WOMAC, Osteoarthritis Research Society International, KOOS, Drug development, Safety, Pain, Vasopressin receptor 2, DVD-Audio, Food, Osteoarthritis, FDA, BLA, Pharmaceutical industry

TAMPA, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PCRX-201 (enekinragene inzadenovec), the company’s novel, intra-articular helper-dependent adenovirus (HDAd) gene therapy product candidate that codes for interleukin-1 receptor antagonist (IL-1Ra), for the treatment of osteoarthritis of the knee.

Key Points: 
  • PCRX-201 was well tolerated, with efficacy observed through at least 52 weeks at all doses and cohorts.
  • Preliminary 36-week data were presented at the Osteoarthritis Research Society International (OARSI) 2023 World Congress, the premier annual international forum in osteoarthritis research and treatment.
  • The 52-week data have been accepted for presentation at OARSI 2024 taking place in Vienna, Austria in April 2024 and the company expects to present 104-week efficacy and safety data later this year.
  • PCRX-201 was also granted Advanced Therapy Medicinal Products (ATMP) designation by the European Medicines Agency in May 2023.

Summit Health Names Timothy Reish, M.D., Chair of Orthopedics and Sports Medicine, Pain Management and Podiatry

Retrieved on: 
Tuesday, April 2, 2024
Health, Surgery, Practice Management, Physical Therapy, Other Health, Managed Care, General Health, Knee, Shoulder, Orthopedic surgery, Patient, Franklin Avenue, Research, Pain management, Elbow, Summit Health, Summit, Sports medicine, Dentistry

Timothy Reish, M.D., has been named Chair of Orthopedics and Sports Medicine, Pain Management and Podiatry of Summit Health’s NY South region.

Key Points: 
  • Timothy Reish, M.D., has been named Chair of Orthopedics and Sports Medicine, Pain Management and Podiatry of Summit Health’s NY South region.
  • He has been a practicing Orthopedic Surgeon in New York City for more than 20 years.
  • “We are thrilled that Dr. Reish will be leading three of our key departments that are essential to the health and well-being of our patients throughout their lifetime,” said Christine Masterson, M.D., executive vice president at Summit Health.
  • “I look forward to helping our Orthopedics, and Sports Medicine, Pain Management and Podiatry departments stay at the forefront of healthcare by offering the latest advancements and cutting-edge techniques in the fields of Orthopedics and Sports Medicine, Pain Management and Podiatry,” said Dr. Reish.

Miach Orthopaedics Raises $20 Million in Series B Extension

Retrieved on: 
Tuesday, April 2, 2024
Health, Surgery, Health Technology, Physical Therapy, Other Health, General Health, Biotechnology, Knee, Tears, Growth, Orthopedic surgery, 2018 Chinese Super League, Skiing, Artem, Patient, ACL, Anterior cruciate ligament, Athlete, NFLPA, Football, Innovation system, Basketball, MLSPA, NFL, Dentistry

Miach Orthopaedics, Inc. , a company transforming the treatment of anterior cruciate ligament (ACL) tears from reconstruction to restoration with the Bridge-Enhanced ACL Restoration (BEAR®) Implant, today announced closing of a $20 million Series B extension financing round.

Key Points: 
  • Miach Orthopaedics, Inc. , a company transforming the treatment of anterior cruciate ligament (ACL) tears from reconstruction to restoration with the Bridge-Enhanced ACL Restoration (BEAR®) Implant, today announced closing of a $20 million Series B extension financing round.
  • The BEAR Implant is the first disruptive technology in ACL tear treatment in more than 30 years.
  • It is a paradigm shift from the current standard of care – reconstruction that replaces the ACL with a graft.
  • “This Series B extension diversifies Miach’s investor group and provides additional resources to further market growth in the U.S. toward the goal of establishing the BEAR Implant as a new standard of care for ACL tears.”
    For more information about the BEAR Implant, visit miachortho.com .

All-new 2025 INFINITI QX80 reimagines the luxury SUV

Retrieved on: 
Wednesday, March 20, 2024
Retail, Automotive Manufacturing, Manufacturing, Other Automotive, Women, Performance & Special Interest, Luxury, Off-Road Trucks & SUVs, Parenting, Men, General Automotive, Aftermarket, Family, Automotive, Consumer, Vehicle Technology, Knee, Friends, Friction, Light-emitting diode, 4WD, Child, Eye, Classic, USB, System, Cruise control, Elegance, Safety, Access, Torque, Accessibility, Language, Invisible Hood, Hand, Projection, Personal, Snow, Acceleration, Google Maps, Lane departure warning system, Tri-Power, LUXE, Grill, Aluminium, LED, SUV, Engineering, Element, Temperature, Attention, Smartphone, Journey, Heat, Paint, Light, Water, Atmosphere, Lighting, Music, Telescopic sight

The all-new 2025 INFINITI QX80 is the first model to showcase the latest evolution of INFINITI design, building on long-standing expertise in craftsmanship and detailing.

Key Points: 
  • The all-new 2025 INFINITI QX80 is the first model to showcase the latest evolution of INFINITI design, building on long-standing expertise in craftsmanship and detailing.
  • The 2025 INFINITI QX80 is the first vehicle in the full-size luxury SUV segment with Klipsch® premium audio systems, reflecting the priority luxury clients place on highly accurate, lifelike sound for entertainment.
  • Luggage space has increased in the all-new 2025 INFINITI QX80, making it even simpler to bring along all of life’s needs.
  • As the flagship SUV in the INFINITI range, the 2025 QX80 delivers confident, capable performance balanced with refinement.

LuskinOIC Partners with the Center for Cerebral Palsy at UCLA to Host Annual Cerebral Palsy Professional Conference and Family Forum on March 23

Retrieved on: 
Tuesday, March 19, 2024
Family, Health, Consumer, Neurology, Other Health, Children, General Health, Community, Knee, Spasticity, DPT, Cerebral palsy, Conference, Neurotoxin, PCS, Doctor of Philosophy, MD, Functional, Physical disability, CP, Bangladesh Technical Education Board, Active Life: Outdoor Challenge, UCLA, Social

On Saturday, March 23, 2024, LuskinOIC and the Center for Cerebral Palsy at UCLA will offer education for professionals, people with cerebral palsy and family members affected by cerebral palsy.

Key Points: 
  • On Saturday, March 23, 2024, LuskinOIC and the Center for Cerebral Palsy at UCLA will offer education for professionals, people with cerebral palsy and family members affected by cerebral palsy.
  • The conference takes place during National Cerebral Palsy Awareness month.
  • Registration is required for both the Professional Conference Agenda & Registration and Family Forum Agenda & Registration .
  • Symposium sponsors include the Cerebral Palsy Foundation, the Shapiro Family Foundation, and the Tarjan Center.

World’s First Total Knee Replacement Patient Treated with PolarisAR Breakthrough Mixed-Reality Surgical Guidance System

Retrieved on: 
Monday, March 18, 2024
Technology, Medical Devices, Surgery, Hospitals, FDA, Software, Other Health, General Health, Health, Data Management, Stellar, Knee, TKA, Surgeon, Environment, Hospital, Workflow, Medical device

PolarisAR , a developer of advanced mixed-reality surgical guidance technology, announced the first total knee arthroplasty (TKA) using its STELLAR Knee mixed-reality surgical guidance system.

Key Points: 
  • PolarisAR , a developer of advanced mixed-reality surgical guidance technology, announced the first total knee arthroplasty (TKA) using its STELLAR Knee mixed-reality surgical guidance system.
  • View the full release here: https://www.businesswire.com/news/home/20240318792314/en/
    The world's first total knee arthroplasty (TKA) was performed using the breakthrough STELLAR Knee mixed-reality surgical guidance system from PolarisAR.
  • STELLAR Knee is a mixed-reality surgical navigation platform that guides TKA procedures by displaying measured and computed data overlaid directly in a 3D environment.
  • The STELLAR Knee system is designed to offer precise control over intraoperative variables compared to traditional instruments, navigation systems, and first-generation augmented reality.

REGENATIVE LABS' LATEST PUBLISHED STUDY DEMONSTRATES THE SAFETY AND EFFICACY OF WHARTON'S JELLY CONNECTIVE TISSUE ALLOGRAFT FOR ROTATOR CUFF TEARS

Retrieved on: 
Thursday, April 4, 2024
Knee, MDPI, Stiffness, Shoulder, Safety, Hip, Wharton's jelly, Rotator cuff, Patient, Research, Rehabilitation, Quality of life, Manager, Efficacy, WOMAC, Regenerative medicine, Quality, Literature, Spine, Orthopedic surgery, Pain, Calendar, Physician, Injury, WJ, Medicine, Dentistry

PENSACOLA, Fla., April 4, 2024 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces the publication of a study exhibiting the safety and efficacy of Wharton's Jelly connective tissue allograft for rotator cuff tears.

Key Points: 
  • PENSACOLA, Fla., April 4, 2024 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces the publication of a study exhibiting the safety and efficacy of Wharton's Jelly connective tissue allograft for rotator cuff tears.
  • Patients in need of rotator cuff repairs often seek minimally invasive options, making Wharton's Jelly a promising alternative for musculoskeletal defects.
  • Utilizing the structural connective tissue allografts has allowed many patients to avoid surgery altogether and significantly improve their quality of life."
  • The study titled "Safety and Efficacy of Wharton's Jelly Connective Tissue Allograft for Rotator Cuff Tears," was published by MDPI and can be accessed in its entirety here.